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Abstracts / Biol Blood Marrow Transplant 21 (2015) S171eS184 S179were 13,6 ng/ml (range: 4,9-26,7 ng/ml) and 100% of the pa-
tients were in the insufﬁciency range levels (<30 ng/ml). Me-
dianPTHi levelswere62,6pg/ml (range:24,4-223,7pg/ml), and
46% of the patients had secondary hyperparathyroidism. In the
postHCTgroup,median25-OHvitaminD levelswere11,4ng/ml
(range: 4-29,4 ng/ml) and 100%had insuﬁciency levels.Median
PTHi levelswere 68pg/ml (range: 37,4-135,8pg/ml), and56%of
the patients had secondary hyperparathyroidism. 12 patients
had DXA before HCT and 3 (25%) of them had DXA lumbar Z
score less than -2.0. In 19 patients postHCT, 4 (21%) had
decreasedDXAZscore< 2.0.Nodifference couldbeestablished
between autologous or allogeneic HCT in any measurement.
Only the presence of chronic graft vs host disease (GVHD) was
associated with higher PTH levels by ANOVA test. None of the
other variables were associated with acute or chronic GVHD.
Conclusions: HCT patients represent a high-risk group of
developing severe vitamin D deﬁciency, secondary hyper-
parathyroidism and decreased DXA levels. These data are a
warning that this population of patients requires early inter-
vention toprevent long-termcomplications. This report is the
initial evaluation for the development and treatment of bone
health in a prospective matter in HCT patients in our center.228
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Leukemia relapses occurring in donor cells, so-called donor cell
leukemias (DCL) after allogeneic hematopoietic stem cell
transplantationhave been reported in several cases and still are
considered as rare diseases. Cytogenetic analysis, ﬂow cytom-
etryandmolecular testinghavebeenused to conﬁrm this event
in the cases so far reported. The incidence of this condition is
largelyunknown,aswellas the resultsof its treatment.Wehave
prospectively searched for DCL in a 12-year period, in a single
institution. In a group of 106 consecutive patients allografted
because of leukemia we have identiﬁed 7 cases of DCL; six of
themwere allografted because of relapsed acute lymphoblastic
leukemia (ALL) and one because of paroxysmal nocturnal he-
moglobinuria/aplastic anemia; these ﬁgures suggest that the
real incidence of DCL has been underestimated in previous
studies. All the patients were allografted from HLA-identical
siblings, employing a reduced-intensity conditioning regimen.
The cases appeared with median of 10 months after the allo-
graft; the number of blast cells when the leukemic activity
ensued was above 50% in all cases, whereas the chimerism
studies revealedmore than 90% cells of donor origin. The origin
of the leukemia cellswas shownbymicrosatellites andwith sex
mismatch. Six patients with lymphoblastic DCL were treated
prospectively with a pediatric-inspired combined chemo-
therapy schedule designed for “de novo” ALL patients. A com-
plete responsewas obtained in 3/6 patientswith lymphoblastic
DCL, these patients being alive in a complete remission at 11,12
and 98 months after the diagnosis of DCL. The long-term DCL
survivors remain full chimeras and did not need a second
transplant. It is concluded that the prevalence of DCL may behigher if it is prospectively looked for, and that acceptable
therapeutic results are obtained if patients are treated as “do
novo” leukemias employing combined chemotherapy.229
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Background: Quality of life (QOL) is an important consid-
eration in the counseling, implementation, and post
treatment management of arduous treatments for life-
threatening conditions, such as allogeneic hematopoietic cell
transplantation (allo-HCT).
Material and Methods: QOL was analyzed in leukemia pa-
tients who underwent allo-HCT using reduced intensity
conditioning (RIC) on an outpatient basis at either the Centro
de Hematología y Medicina Interna de Puebla of the Clínica
Ruiz or the Hematology Service of the Internal Medicine
Department of the Hospital “Dr. José Eleuterio González” of
the Universidad Autónoma de Nuevo León, and who had
survived above 12 months after the allograft, who could be
approached, who were in a continued complete remission-
with or without graft versus host disease and who were
willing to respond to the questionnaire. Thirty-ﬁve patients
fulﬁlling these requirements were included, and a sex and
age-matched group of 35 reference subjects was also studied.
Results: Allografted patients were found to have a slightly
better mental component summary than the reference sub-
jects (53.23 versus 48.66 points, p ¼ 0.01), whereas the
physical component summary did not show a difference
(54.53 versus 52.05 points, p ¼ 0.59). Most of the differences
between allografted individuals and reference subjects con-
trols were not signiﬁcant.
Conclusions: These data suggest that allografted individuals
employing our RIC regimen, enjoy a health-related quality of
life similar to that of reference subjects, adding, another
advantage of this method of conducting stem cell allograft-
ing. However, more work needs to be done to elucidate the
impact of RIC on QOL post-allo-HCT.230
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